Renaissance Capital logo

Allogene Therapeutics Priced, Nasdaq: ALLO

Phase 1 biotech developing off-the-shelf CAR T cell cancer therapies.

Industry: Health Care

Latest Trade: $26.55 0.00 (0.0%)

First Day Return: +38.9%

Return from IPO: +47.5%

Industry: Health Care

We are a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. We are developing a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Our engineered T cells are allogeneic, meaning they are derived from healthy donors for intended use in any patient, rather than from an individual patient for that patient’s use, as in the case of autologous T cells. We believe this key difference will enable us to deliver readily available treatments faster, more reliably, at greater scale, and to more patients. In collaboration with Servier, we are developing UCART19, a CAR T cell product candidate targeting CD19 and is being studied in clinical trials in patients with R/R B-cell precursor ALL. We expect UCART19 to be advanced to potential registrational trials in the second half of 2019. We also plan to submit an IND in the first half of 2019 for our second allogeneic anti-CD19 CAR T cell product candidate, ALLO-501, for the treatment of NHL.
more less
IPO News for Allogene Therapeutics
more
IPO Data
IPO File Date 09/14/2018
Offer Price $18.00
Price Range $16.00 - $18.00
Offer Shares (mm) 18.0
Deal Size ($mm) $324
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 10/10/2018
Offer Price $18.00
Price Range $16.00 - $18.00
Offer Shares (mm) 18.0
Deal Size ($mm) $324
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters South San Francisco, CA
Founded 2017
Employees 78
Website www.allogene.com